A Phase 1 Trial of Duvelisib and Oral Azacitidine in Relapsed/Refractory T-Cell Lymphoma.

Hematol OncolSep 1, 2026
Clinical ResearchHematologyOncology (Medical)Open access

Hayder Saeed, Melanie Mediavilla Varela, Eva Sahakian et al.

✦ AI-curated · Sources linked

In 30 seconds

This Phase I trial evaluated the combination of duvelisib and oral azacitidine in 14 patients with relapsed/refractory T-cell lymphoma. The study aimed to determine the maximum tolerated dose and reported an overall response rate of 46%, with 31% achieving complete responses. The median progression-free survival was 2.2 months, and median overall survival was 10.2 months.

Key findings

  • Overall response rate was 46%, with 31% achieving complete responses.
  • Median progression-free survival was 2.2 months.
  • Median overall survival was 10.2 months.
  • Grade ≥3 toxicities included neutropenia (29%) and anemia (21%).

Why it matters

The findings suggest that the combination of duvelisib and azacitidine may offer a new therapeutic option for patients with relapsed/refractory T-cell lymphoma, particularly for those with the T-follicular-helper phenotype.

Source

PubMed · PMID 42545812Free full text on PubMed Central

Published in Hematol Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchOncology (Medical)

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

This phase 3 randomized clinical trial evaluated the efficacy and safety of osimertinib combined with chemotherapy versus osimertinib alone in 294 patients with advanced non-small cell lung cancer (NSCLC) harboring…

JAMASep 8, 2026Open accessRead summary
Clinical ResearchHematology

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

This phase 2 randomized trial compared azacitidine plus venetoclax to induction chemotherapy in 172 previously untreated adults with acute myeloid leukemia (AML) eligible for induction.

N Engl J MedSep 3, 2026Read summary
Clinical ResearchPsychiatry

The efficacy of modified psychodynamic psychotherapy for patients with schizophrenia-spectrum disorders in Germany: a prospective, single-centre, assessor-blinded, parallel-group, randomised controlled trial.

This randomized controlled trial evaluated the efficacy of Modified Psychodynamic Psychotherapy for Schizophrenia (MPP-S) combined with treatment as usual (TAU) in 130 outpatients with schizophrenia-spectrum disorders…

Lancet PsychiatrySep 10, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.